Acupuncture Feasibility Trial for Dyspnea in Lung Cancer

Study summary

This is a single arm clinical trial to establish the feasibility of conducting a clinical trial of acupuncture in reducing dyspnea among lung cancer survivors who have completed chemoradiotherapy. Twelve subjects with dyspnea will be recruited to this clinical trial. Up to 10 sessions of acupuncture will be delivered over the course of 8-10 weeks. The primary outcome will be dyspnea as measured by the English version of the Cancer Dyspnea Scale at the completion of the intervention.

Ask AI to explain this study

Start here

Key things to know

Main goalSupportive Care

This describes the study’s primary purpose.

What is being studiedAcupuncture

The study team can explain what participation involves.

Who it may be forLung Cancer · Dyspnea

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jul 23, 2019 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Abramson Cancer Center at Penn Medicine

Study sponsor

Study overview

What this study is about

Purpose: Supportive Care
Study type: Interventional
Phase: Phase 1
Sponsor: Abramson Cancer Center at Penn Medicine
Interventions being studied: Procedure: Acupuncture

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach

Radiation therapy→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Diagnosis of Lung Cancer (Non small cell and small cell both eligible)
Completion of concurrent CRT at least 6 months prior to randomization.
Dyspnea which worsened after Chemoradiotherapy, leading to a ATS dyspnea score greater than or equal to 2 (Walks slower than people of the same age on the level because of breathlessness or has to stop for breath when walking at own pace on level)
Ability to understand written English -Willingness to adhere to all study-related procedures
Age 18 years old
ECOG Performance Status 1-3

Reasons someone may not be able to joinExclusion criteria

Current receipt of therapy for treatment related pneumonitis for 3 weeks.
Surgical resection of this LC (lobectomy or pneumonectomy)
Another organic cause of dyspnea necessitating treatment (eg pleural effusion appropriate for thoracentesis, rapidly progressive intrathoracic recurrence, symptomatic pulmonary embolus after CRT, untreated anemia with hemoglobin8 g/dL)
Current bleeding disorder by history
Life expectancy of 12 weeks, as assessed by primary oncologist

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Abramson Cancer Center of the University of PennsylvaniaPhiladelphia, Pennsylvania

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 23, 2019. Always confirm current availability with the study team.

View original record ↗